Table 2.
The relationships between NLR and mortality in patients with comorbid CHD and hypertension.
| Characteristic | Model 1 | P value | Model 2 | P value | Model 3 | P value |
|---|---|---|---|---|---|---|
| HR (95% CI) | HR (95% CI) | HR (95% CI) | ||||
| All-cause mortality | ||||||
| NLR | 1.26(1.22,1.29) | < 0.0001 | 1.20(1.16, 1.23) | < 0.0001 | 1.16(1.13, 1.20) | < 0.0001 |
| NLR category | ||||||
| Lower NLR | Ref | Ref | Ref | |||
| Higher NLR | 2.00(1.84, 2.16) | < 0.0001 | 1.60(1.45, 1.75) | < 0.0001 | 1.46(1.30, 1.62) | < 0.0001 |
| Cardiovascular mortality | ||||||
| NLR | 1.27(1.23, 1.31) | 1.22(1.17, 1.26) | 1.19(1.13, 1.24) | |||
| NLR category | ||||||
| Lower NLR | Ref | Ref | Ref | |||
| Higher NLR | 2.20(2.01, 2.40) | < 0.0001 | 1.73(1.49, 1.97) | < 0.0001 | 1.58(1.33, 1.82) | < 0.0001 |
Model 1 was unadjusted; Model 2 was adjusted for age, sex, race, heart failure, and cancer; Model 3 was adjusted for age, sex, race, heart failure, cancer, education, smoking conditions, BMI, HDL, albumin, TC, eGFR.